Trade Veracyte Inc - VCYT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.21 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 31.7 |
| Open | 31.37 |
| 1-Year Change | 62.45% |
| Day's Range | 30.97 - 31.53 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 15, 2025 | 31.70 | 0.30 | 0.96% | 31.40 | 32.11 | 31.04 |
| Apr 14, 2025 | 32.09 | 0.16 | 0.50% | 31.93 | 32.66 | 30.99 |
| Apr 11, 2025 | 31.73 | 2.26 | 7.67% | 29.47 | 31.73 | 29.46 |
| Apr 10, 2025 | 30.19 | -0.88 | -2.83% | 31.07 | 31.07 | 28.63 |
| Apr 9, 2025 | 32.54 | 5.59 | 20.74% | 26.95 | 33.10 | 26.95 |
| Apr 8, 2025 | 28.84 | -1.18 | -3.93% | 30.02 | 30.89 | 28.63 |
| Apr 7, 2025 | 29.48 | 2.51 | 9.31% | 26.97 | 30.66 | 26.90 |
| Apr 4, 2025 | 28.86 | 1.40 | 5.10% | 27.46 | 29.26 | 27.32 |
| Apr 3, 2025 | 28.40 | -0.01 | -0.04% | 28.41 | 29.26 | 27.92 |
| Apr 2, 2025 | 30.07 | 1.42 | 4.96% | 28.65 | 30.80 | 28.65 |
| Apr 1, 2025 | 29.48 | 0.28 | 0.96% | 29.20 | 30.47 | 28.47 |
| Mar 31, 2025 | 29.55 | 0.43 | 1.48% | 29.12 | 30.06 | 28.47 |
| Mar 28, 2025 | 30.06 | -0.68 | -2.21% | 30.74 | 30.74 | 29.63 |
| Mar 27, 2025 | 31.02 | 0.40 | 1.31% | 30.62 | 31.69 | 30.08 |
| Mar 26, 2025 | 31.01 | -2.61 | -7.76% | 33.62 | 33.62 | 30.55 |
| Mar 25, 2025 | 33.64 | 0.79 | 2.40% | 32.85 | 33.64 | 32.46 |
| Mar 24, 2025 | 33.06 | 1.10 | 3.44% | 31.96 | 33.16 | 31.96 |
| Mar 21, 2025 | 31.73 | 0.37 | 1.18% | 31.36 | 31.99 | 30.64 |
| Mar 20, 2025 | 31.77 | 0.56 | 1.79% | 31.21 | 32.67 | 31.20 |
| Mar 19, 2025 | 31.72 | 0.44 | 1.41% | 31.28 | 32.55 | 30.66 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Veracyte Inc Company profile
About Veracyte Inc
Veracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. It offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. It also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Veracyte Inc revenues increased 87% to $219.5M. Net loss increased from $34.9M to $75.6M. Revenues reflect United States segment increase of 83% to $201M, International segment increase from $7.9M to $18.5M. Higher net loss reflects Selling and marketing - Balancing value increase of 54% to $75.4M (expense), General & Administrative Expenses increase of 47% to $42.2M (expense).
Equity composition
Common Stock, $0.001 Par, 10/13, 125M auth., 20,989,890 issd., Insiders Own 76.17%
| Industry: | Bio Diagnostics & Testing |
6000 Shoreline Court, Suite 300
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com